Brain+ A/S
CSE:BRAINP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0748
0.134
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Brain+ A/S
Cash Equivalents
Brain+ A/S
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Brain+ A/S
CSE:BRAINP
|
Cash Equivalents
kr3.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
NNIT A/S
CSE:NNIT
|
Cash Equivalents
kr254m
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
M
|
Monsenso A/S
CSE:MONSO
|
Cash Equivalents
kr1.8m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Brain+ A/S
Glance View
Brain+ A/S is engaged in the developing of medical software to detect and treat the cognitive symptoms of dementia and the most common cause of dementia, namely Alzheimer's disease. The firm focuses on the development of digital treatment for dementia and Alzheimer’s disease by digital therapeutics. The Company’s main activities include the development of Cognitive Stimulation Therapy for the treatment of dementia, Computerized Cognitive Training for the treatment of earlier stages of Alzheimer’s and Starry Night memory test for early detection and monitoring of Alzheimer’s. The company offers a product called Digital CST assistant giving access to Cognitive Stimulation Therapy sessions, available in Danish.
See Also
What is Brain+ A/S's Cash Equivalents?
Cash Equivalents
3.1m
DKK
Based on the financial report for Dec 31, 2023, Brain+ A/S's Cash Equivalents amounts to 3.1m DKK.
What is Brain+ A/S's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
31%
Over the last year, the Cash Equivalents growth was -52%. The average annual Cash Equivalents growth rates for Brain+ A/S have been 31% over the past three years .
You don't have any saved screeners yet